



Attorney Docket No.: 5686.200-US

Receipt  
PATENT 0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Request for Corrected Filing Receipt
2. Copy of Filing Receipt

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks  
Washington, DC 20231

on April 24, 2000.

Carol McFarlane  
(name of person mailing paper)

Carol McFarlane  
(signature of person mailing paper)



Attorney Docket No.: 5686.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants filed the above-captioned application on January 14, 2000.

The filing receipt received by Applicants incorrectly indicates the country of residence for inventor Michael D. Johnson as Denmark. The correct country of residence for inventor Johnson is Cardiff, California, U.S.A. A copy of the filing receipt is attached to this request.

Applicants therefore request the issuance of a corrected filing receipt with the correct country of residence.

Respectfully submitted,

Date: April 24, 2000


Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Elan



HC BSHN

file:///c:/APPS/preexam/correspondence/1\_A.htm


**FILING RECEIPT**

\*OC000000005041904\*

**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**

 Address: ASSISTANT SECRETARY AND  
 COMMISSIONER OF PATENT AND TRADEMARKS  
 Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/483,504	01/14/2000	1614	690	5686.200-us	-	15	1

 Novo Nordisk of North America Inc  
 405 Lexington Avenue  
 Suite 6400  
 New York, NY 10017


Date Mailed: 04/11/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**
 Min Teng, San Diego, CA ;  
 Larry Kenneth Truesdale, San Diego, CA ;  
 Dilip Bhunraikar, San Diego, CA ;  
 Dan Kiel, San Diego, CA ;  
 Michael D Johnson, Cardiff, DENMARK;  
 Christine Thomas, San Diego, CA ;  
 Anker Steen Jorgensen, Copenhagen O, DENMARK;  
 Peter Madsen, Bagsvaerd, DENMARK;  
 Preben Houllberg Olesen, Copenhagen nv, DENMARK;  
 Liselotte Bjerre Knudsen, Valby, DENMARK;  
 Ingrid Vivika Petterson, Frederiksberg, DENMARK;  
 Johannes Cornelis De Jong, Bagsvaerd, DENMARK;  
 Behrens Carsten, Copenhagen N, DENMARK;  
 Janos Tibor Kodra, Copenhagen O, DENMARK;  
 Jesper Lau, Farum, DENMARK;
**Continuing Data as Claimed by Applicant**

THIS APPLN CLAIMS BENEFIT OF 60/116,116 01/15/1999

**Foreign Applications**

DENMARK PA199900041 01/15/1999

If Required, Foreign Filing License Granted 04/10/2000

\*\*

Title

Non-peptide glp-1 agonists

Preliminary Class

514



Data entry by : NEWTON, WILLIAM

Team : OIPE

Date: 04/11/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to: